Emilia Romagna (ITH5)

Emilia-Romagna is a region in the northeast of Italy comprising the historical regions of Emilia and Romagna, it has a population of 4.5 million. It is home to the University of Bologna, which was founded in 1088 and is the oldest university in the world.

The region has a focus on the emerging fields of regenerative and restorative medicine, as well as pharmaceutical and omics sciences and inclusive services and usable technologies for healthy living and active aging.

​

Emilia-Romagna  is involved in a number of major initiatives in the field of personalised medicine including Hologene, Custom Implants, Italian Infrastructure for Regenerative Medicine, SUPER  HPC and Big Data and Italian Biobanks network.

Regional website

http://www.art-er.it

Policy document (RIS3): Yes

Policy document PM@RIS3: Yes

Policy documents

1. National level: SNSI - National smart specialization  https://www.invitalia.it/chi-siamo/area-media/storie/smart-specialisation-strategy-le-priorita-nazionali-per-lo-sviluppo-del-paese 

2. National level: ALISEI applied life science national cluster strategic plan  http://www.clusteralisei.it/en/strategic-plan/ 

Major initiatives

1. Hologene 7  http://www.hg7porfesr.eu/en/homepage-2/

2. Hologene 7 2.0

3. Custom Implants  http://www.custom-implants.it/

4. IRMI - Italian Infrastructure for Regenerative Medicine  http://www.clusteralisei.it/progetti/irmi/

5. SUPER  HPC and Big Data 

6. BBMRI.it  Italian Biobanks network  https://www.bbmri.it/lista-biobanche/

Is the region represented in: Horizon2020; Regional Smart Specialisation Strategy Platforms/Partnerships (RIS3); EIT Health/InnoStars/Regional Innovation Scheme (RIS); other?

​

1. BBMRI  EUS3 Platform - Personalized Medicine

2. H2020 - SMEINST - Oncosmart - ONCOlogic patient profiling and personalized treatment through SMART bedside diagnostics

3. H2020- SMEINST- BIOFOSTE - Clinical validation of a BIOmarker panel For OSTEoarthritis diagnosis: BIOFOSTE

4. H2020 - SC1- ADIPOA2 - Clinical trial of autologous adipose-derived mesenchymal stromal cells (ASC) in the treatment of mild to moderate osteoarthritis